| Dr Javier F Sevilla, MD | |
|
1520 N Senate Ave, Indianapolis, IN 46202-2213 | |
| (317) 962-8893 | |
| (317) 962-2990 |
| Full Name | Dr Javier F Sevilla |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 1520 N Senate Ave, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023076775 | NPI | - | NPPES |
| 200378040 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01056089A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Family Physicians, Inc. | 7911992797 | 424 |
News Archive
Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.
Everyday Health, Inc., a leading digital health and wellness company, today announced a strategic partnership with Wildflower Health. Through this partnership, Everyday Health expands its suite of offerings to help health plans and employers reach and engage pregnant women earlier in their pregnancies to improve health outcomes and reduce medical costs.
The 16th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) ended on Thursday in Addis Ababa, Ethiopia, where "the final plenary session ... left the audience with a notion of hope and urgency that despite the Global Fund's cancellation of Round 11 disbursements, the organization will continue to campaign, raise funds and place pressure on governments in both the donor and recipient arenas," an ICASA news article reports (12/8).
In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.
› Verified 1 days ago
| Entity Name | University Family Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043275787 PECOS PAC ID: 7911992797 Enrollment ID: O20040420000393 |
News Archive
Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.
Everyday Health, Inc., a leading digital health and wellness company, today announced a strategic partnership with Wildflower Health. Through this partnership, Everyday Health expands its suite of offerings to help health plans and employers reach and engage pregnant women earlier in their pregnancies to improve health outcomes and reduce medical costs.
The 16th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) ended on Thursday in Addis Ababa, Ethiopia, where "the final plenary session ... left the audience with a notion of hope and urgency that despite the Global Fund's cancellation of Round 11 disbursements, the organization will continue to campaign, raise funds and place pressure on governments in both the donor and recipient arenas," an ICASA news article reports (12/8).
In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Javier F Sevilla, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Javier F Sevilla, MD 1520 N Senate Ave, Indianapolis, IN 46202-2213 Ph: (317) 962-8893 |
News Archive
Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.
Everyday Health, Inc., a leading digital health and wellness company, today announced a strategic partnership with Wildflower Health. Through this partnership, Everyday Health expands its suite of offerings to help health plans and employers reach and engage pregnant women earlier in their pregnancies to improve health outcomes and reduce medical costs.
The 16th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) ended on Thursday in Addis Ababa, Ethiopia, where "the final plenary session ... left the audience with a notion of hope and urgency that despite the Global Fund's cancellation of Round 11 disbursements, the organization will continue to campaign, raise funds and place pressure on governments in both the donor and recipient arenas," an ICASA news article reports (12/8).
In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.
› Verified 1 days ago
Leigha Marie Murphy, NP Family Medicine Medicare: Medicare Enrolled Practice Location: 8904 Bash St Ste B, Indianapolis, IN 46256 Phone: 317-735-6001 Fax: 855-450-1177 | |
Donald H Lauer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1250 E County Line Rd, Suite 9, Indianapolis, IN 46227 Phone: 317-881-9797 Fax: 317-881-4156 | |
Robert Kiess Newton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9560 E 59th St, Indianapolis, IN 46216 Phone: 317-621-1700 Fax: 317-621-1711 | |
Dr. Bernard M Herbst, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5839 E Washington St, Indianapolis, IN 46219 Phone: 317-353-9777 Fax: 317-357-6922 | |
Teresa Trierweiler, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4880 Century Plaza Rd, Suite 200, Indianapolis, IN 46254 Phone: 317-293-4113 Fax: 317-290-2542 | |
Dr. Phumeza Msikinya, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8920 Southpointe Dr Ste B, Indianapolis, IN 46227 Phone: 317-497-1900 | |
Ruben Hernan Hernandez Mondragon, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1040 Wishard Blvd, Indianapolis, IN 46202 Phone: 317-962-8893 Fax: 317-962-2990 |